Dose finding and safety analysis of inecalcitol in combination with docetaxel-prednisone regimen in hormone-refractory prostate cancer (HRPC) patients (pts)

被引：0
|
作者：
Medioni, J. [1 ]
Deplanque, G. [2 ]
Maurina, T. [3 ]
Ferrero, J. M. [4 ]
Rodier, J. M. [5 ]
Raymond, E. [5 ]
Allyon, J. [1 ]
Kalla, S. [2 ]
Dufour-Lamartinie, J. F. [6 ]
Oudard, S. [1 ]
机构：
[1] Hop Europeen Georges Pompidou, Paris, France
[2] Ctr Hosp St Joseph, Paris, France
[3] Ctr Hosp Univ Jean Minjoz, Besancon, France
[4] Ctr Antoine Lacassagne, F-06054 Nice, France
[5] Hop Beaujon, Clichy, France
[6] Hybrigenics, Oncol, Paris, France
来源：
EJC SUPPLEMENTS | 2009年 / 7卷 / 02期
关键词：
D O I：
10.1016/S1359-6349(09)71408-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：415 / 415
页数：1
相关论文
共 50 条
  • [41] Safety and Efficacy of Cabazitaxel in the Docetaxel-Treated Patients with Hormone-Refractory Prostate Cancer
    Calcagno, Fabien
    Nguyen, Thierry
    Dobi, Erion
    Villanueva, Cristian
    Curtit, Elsa
    Kim, Stefano
    Montcuquet, Philippe
    Kleinclauss, Francois
    Pivot, Xavier
    Thiery-Vuillemin, Antoine
    CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2013, 7 : 1 - 12
  • [42] A combination docetaxel-capecitabine in patients (pts) with hormone refractory advanced prostate cancer
    Ferrero, Jean-Marc
    Oudard, Stephane
    Chamorey, Emmanuel
    Berdah, Jean Francois
    Dides, Sabine
    Lesbats, Gerard
    Cavaglione, Gerard
    Nouyrigat, Pierre
    Foa, Cyril
    Guillet, Pierre
    ANNALS OF ONCOLOGY, 2004, 15 : 116 - 116
  • [43] Docetaxel (D) plus estramustine (E) versus D alone in patients (pts) with hormone-refractory prostate cancer (HRPC): Updated analysis of a phase II randomized trial
    Mousseau, Mireille
    Joly, Florence
    Priou, Franck
    Zannetti, Alain
    Ravaud, Alain
    Kerbrat, Pierre
    Paule, Bernard
    Touze, Florence
    Ecstein-Fraisse, Evelyne
    Eymard, Jean-Christophe
    ANNALS OF ONCOLOGY, 2004, 15 : 114 - 114
  • [44] Docetaxel, estramustine and prednisone for hormone-refractory prostate cancer: A single-center experience
    Boehmer, A
    Anastasiadis, AG
    Feyerabend, S
    Nagele, U
    Kuczyk, M
    Schilling, D
    Corvin, S
    Merseburger, AS
    Stenzl, A
    ANTICANCER RESEARCH, 2005, 25 (6C) : 4481 - 4486
  • [45] Impact of age at diagnosis on survival of hormone-refractory prostate cancer (HRPC) patients
    Humphreys, M. R.
    Ma, C.
    Sridhar, S. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [46] Randomized study of docetaxel (D) and dexamethasone (DX) with low or high dose estramustine (E) for patients with advanced hormone-refractory prostate cancer (HRPC).
    Nelius, T.
    Klatte, T.
    Reiher, F.
    Filleur, S.
    Yap, R.
    Allhoff, E. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 254S - 254S
  • [47] Phase I study of picoplatin and docetaxel (D) with prednisone (P) in patients (pts) with chemotherapy-naive metastatic hormone refractory prostate cancer (HRPC)
    Roman, L.
    Karlov, P.
    Kaprin, A.
    Gladkov, O.
    Breitz, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [48] Docetaxel (D) plus estramustine (E) as second line chemotherapy after D alone, for patients (PTS) with hormone-refractory advanced prostate cancer (HRPC)
    Caffo, Orazio
    Sava, Teodoro
    Comploj, Evi
    Zustovich, Fable
    Giampaolo, Maria Anna
    Segati, Romana
    Sacco, Cosimo
    Perin, Alessandra
    Lucenti, Antonio
    Galligioni, Enzo
    ANNALS OF ONCOLOGY, 2006, 17 : 156 - 156
  • [49] Randomised study of docetaxel (D) and dexamethasone (DX) with low or high dose estramustine (E) for patients with advanced hormone-refractory prostate cancer (HRPC)
    不详
    EUROPEAN UROLOGY SUPPLEMENTS, 2006, 5 (02) : 94 - 94
  • [50] NAVELBIN AS A SECOND LINE TREATMENT FOR PATIENTS WITH HORMONE-REFRACTORY PROSTATE CANCER (HRPC)
    Jana, J. K.
    Rovny, A. R.
    Divisova, K. D.
    Filipensky, P. F.
    EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (06) : 658 - 659
12345